Literature DB >> 24492306

Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

Krista M McCutcheon1, Julia Gray2, Natalie Y Chen3, Keyi Liu3, Minha Park4, Stote Ellsworth3, Ralph A Tripp5, S Mark Tompkins5, Scott K Johnson5, Shelly Samet5, Lenore Pereira6, Lawrence M Kauvar4.   

Abstract

Viral entry targets with therapeutic neutralizing potential are subject to multiple escape mechanisms, including antigenic drift, immune dominance of functionally irrelevant epitopes, and subtle variations in host cell mechanisms. A surprising finding of recent years is that potent neutralizing antibodies to viral epitopes independent of strain exist, but are poorly represented across the diverse human population. Identifying these antibodies and understanding the biology mediating the specific immune response is thus difficult. An effective strategy for meeting this challenge is to incorporate multiplexed antigen screening into a high throughput survey of the memory B cell repertoire from immune individuals. We used this approach to discover suites of cross-clade antibodies directed to conformational epitopes in the stalk region of the influenza A hemagglutinin (HA) protein and to select high-affinity anti-peptide antibodies to the glycoprotein B (gB) of human cytomegalovirus. In each case, our screens revealed a restricted VH and VL germline usage, including published and previously unidentified gene families. The in vivo evolution of paratope specificity with optimal neutralizing activity was understandable after correlating biological activities with kinetic binding and epitope recognition. Iterative feedback between antigen probe design based on structure and function information with high throughput multiplexed screening demonstrated a generally applicable strategy for efficient identification of safe, native, finely tuned antibodies with the potential for high genetic barriers to viral escape.

Entities:  

Keywords:  broadly protective antibodies; cytomegalovirus; fusion; human antibodies; immunoglobulin germline; influenza; monoclonal antibodies; neutralizing antibodies; viral epitopes

Mesh:

Substances:

Year:  2014        PMID: 24492306      PMCID: PMC3984334          DOI: 10.4161/mabs.27760

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  24 in total

1.  Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus.

Authors:  Johan Lantto; Jean M Fletcher; Mats Ohlin
Journal:  Virology       Date:  2003-01-05       Impact factor: 3.616

Review 2.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

3.  Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Authors:  Christy A Thomson; Steve Bryson; Gary R McLean; A Louise Creagh; Emil F Pai; John W Schrader
Journal:  EMBO J       Date:  2008-09-04       Impact factor: 11.598

4.  A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus.

Authors:  M Andreoni; M Faircloth; L Vugler; W J Britt
Journal:  J Virol Methods       Date:  1989-02       Impact factor: 2.014

5.  Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis.

Authors:  Ekaterina Maidji; Susan McDonagh; Olga Genbacev; Takako Tabata; Lenore Pereira
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

6.  Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology.

Authors:  Peter Timmerman; Wouter C Puijk; Rob H Meloen
Journal:  J Mol Recognit       Date:  2007 Sep-Oct       Impact factor: 2.137

7.  UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas.

Authors:  M C Glassy; H H Handley; H Hagiwara; I Royston
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

8.  Influenza virus.

Authors:  R Cottey; C A Rowe; B S Bender
Journal:  Curr Protoc Immunol       Date:  2001-05

9.  Production of a human single-chain variable fragment antibody against esophageal carcinoma.

Authors:  Ming-Yan Xu; Xiao-Hu Xu; Geng-Zhen Chen; Xiao-Ling Deng; Jonathan Li; Xiao-Jun Yu; Mei-Zhen Chen
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

10.  Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.

Authors:  M Ohlin; V A Sundqvist; M Mach; B Wahren; C A Borrebaeck
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  9 in total

1.  Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta.

Authors:  Takako Tabata; Matthew Petitt; Martin Zydek; June Fang-Hoover; Nicholas Larocque; Mitsuru Tsuge; Matthew Gormley; Lawrence M Kauvar; Lenore Pereira
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

2.  A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.

Authors:  Lawrence M Kauvar; Keyi Liu; Minha Park; Neal DeChene; Robert Stephenson; Edgar Tenorio; Stote L Ellsworth; Takako Tabata; Matthew Petitt; Mitsuru Tsuge; June Fang-Hoover; Stuart P Adler; Xiaohong Cui; Michael A McVoy; Lenore Pereira
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

3.  HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex.

Authors:  Martin Zydek; Matthew Petitt; June Fang-Hoover; Barbara Adler; Lawrence M Kauvar; Lenore Pereira; Takako Tabata
Journal:  Viruses       Date:  2014-03-19       Impact factor: 5.048

4.  Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.

Authors:  Adam Vigil; Angeles Estélles; Lawrence M Kauvar; Scott K Johnson; Ralph A Tripp; Michael Wittekind
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Functional Enrichment and Analysis of Antigen-Specific Memory B Cell Antibody Repertoires in PBMCs.

Authors:  Eric Waltari; Aaron McGeever; Natalia Friedland; Peter S Kim; Krista M McCutcheon
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

6.  The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion.

Authors:  Stefan L Oliver; Yi Xing; Dong-Hua Chen; Soung Hun Roh; Grigore D Pintilie; David A Bushnell; Marvin H Sommer; Edward Yang; Andrea Carfi; Wah Chiu; Ann M Arvin
Journal:  PLoS Pathog       Date:  2021-01-07       Impact factor: 6.823

7.  Native Human Antibody to Shr Promotes Mice Survival After Intraperitoneal Challenge With Invasive Group A Streptococcus.

Authors:  Nilanjana Chatterjee; Ya-Shu Huang; Kristin V Lyles; Julie E Morgan; Lawrence M Kauvar; Susanna F Greer; Zehava Eichenbaum
Journal:  J Infect Dis       Date:  2021-04-23       Impact factor: 5.226

8.  High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals.

Authors:  Stefan Ryser; Angeles Estellés; Edgar Tenorio; Lawrence M Kauvar; Mikhail L Gishizky
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

9.  Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.

Authors:  Adam Vigil; Natalia Frias-Staheli; Teresa Carabeo; Michael Wittekind
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.